Company: PTPI
Filing Date: 2025-01-24
Form Type: S-1
Source: 0001410578-25-000047
Chunk: 78

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-01-24
Form: S-1
Chunk 78
---
4                                                                                      | ​ | ​ 
 ​ | (0.37) | ​ | ​ |   | ​ |
|:-----------------------------------------------------------------------------------------------------------------------------------------------------------|:--|:--|-------:|:--|:--|:--|:--|
| Pro forma decrease in net tangible book value per share attributable to the Vivus Adjustments                                                              | ​ | $ |  -0.51 | ​ | ​ | ​ | ​ |
| Pro forma net tangible book value per share as of September 30, 2024, after giving effect to Vivus Adjustments                                             | ​ | $ |  -0.88 | ​ | ​ | ​ | ​ |
| Pro forma as adjusted increase (or decrease) in net tangible book value per share attributable to investors in this offering and the Pro Forma Adjustments | ​ | $ |        | ​ | ​ |   | ​ |
| Pro Forma as adjusted net tangible book value per share after giving effect to this offering                                                               | ​ | ​ |        | ​ | $ |   | ​ |
| Dilution per share to investors participating in this offering                                                                                             | ​ | ​ |        | ​ | $ |   | ​ |

A $1.00 increase in the assumed public offering price of $ per share, which is the last reported sale price of our common stock on The Nasdaq Capital Market on , 2025, would result in a decrease in our as adjusted net tangible book value per share after this offering by approximately $ and the dilution per share to new investors purchasing shares in this offering by $ assuming the number of securities offered by us as set forth on the cover page of this prospectus remains the same, and after deducting the placement agent fees and estimated offering expenses payable by us. A $1.00 decrease in the assumed public offering price of $ per share, which is the last reported sale price of our common stock on The Nasdaq Capital Market on , 2025, would result in a decrease in our as adjusted net tangible book value per share after this offering by approximately $ and the dilution per share to new investors purchasing shares in this offering by $ assuming the number of securities offered by us as set forth on the cover page of this prospectus remains the same, and after the placement agent fees and estimated offering expenses payable by us. We may also increase or decrease the number of securities to be issued in this offering. Each increase (decrease) of 1.0 million Units offered by us would increase (decrease)